To sequence or not to sequence?

Bibliography

• DELTA CO-ORDINATING COMMITTEE: DELTA: a random-ised double-blind controlled trial comparing combina-tions of zidovudine plus didanosine or zalcitabine or zidovudine alone in HIV infected individuals. Lancet (1996) 348:283.
   PubMed Web of Science ®Google Scholar
• CAMERON W, SUN E, MARKOWITZ M eta].: Combinationuse of ritonavir and saquinavir in HIV-infecte d patients: preliminary safety and activity data. XI International Conference on AIDS. Vancouver (July 1996). Abstract Th. B.934.
   Google Scholar
• PERELSON AS, ESSUNGER P, MARKOWITZ M, HO DD: Howlong should treatment be given if we hadan ant iretrovi-ral regimen that completely blocks HIV replication? XI International Conference on AIDS. Vancouver (July 1996). Abstract Th.B .930.
   Google Scholar
• MOYLE GJ: Use of viral resistance patterns to antiretrovi-ral drugs in optimising selection of drug combinations and sequences. Drugs (1996) 52:168–185.
   PubMed Web of Science ®Google Scholar
• D'AQUILA RT, JOHNSON VA, WELLES SL eta].: Zidovudine resistance and 11IV-1 disease prcgression during an-tiretroviral therapy. Ann. Intern. Med. (1995) 122:401–408.
   Google Scholar
• KOZAL MJ, KROODSMA K, WINTERS MA eta].: Didanosine resistance in HIV-infected patients switched from zi-dovudine to didanosine monotherapy. Ann. Intern. Med. (1994) 121:263–268.
   Google Scholar
• SHIRASAKA T, KAVLICK MF, VENO T et al.: Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA (1995) 92:2398–2402.
   PubMed Web of Science ®Google Scholar
• CRAIG C, MOYLE G: The development of resistance of 11IV-1 to ddC. AIDS (In press).
   Google Scholar
• MOYLE G: Activity and role of lamivudine in the treat-ment of adults with human immunodeficiency virus type 1 infection: a review. Exp. Opin. Invest. Drugs (1996) 5:913–924.
   Google Scholar
• WAINBERG MA, SALOMON H, GU Z et aL: Development of 11IV-1 resistance to (-)2'-deoxy-3'-thiacytidine in pa-tients with AIDS or advanced AIDS-related complex. AIDS (1995) 9:351–357.
   PubMed Web of Science ®Google Scholar
• LARDER BA, KEMP SD, HARRIGAN PR: Potential mecha-nism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 269:696–699.
   PubMed Web of Science ®Google Scholar
• JOHNSON VA, WAGNER SF, OVERBAY CB et al.: Drug resistance and viral load in NUCA 3002: a comparative trial of lamivudine (3TC) (high or low dose) /zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced 24 weeks) patients (CD4 cells 100-300/mm3). Fourth International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 55.
   Google Scholar
• KATLAMA C ON BEHALF OF THE CAESAR CO-ORDINAT-ING COMMITTEE: Clinical and survival benefit of 3TC in combination with zidovudine-containing regimens in 11IV-1 infection: interim results of the CAESAR study. 3rd International Congress on Drug Therapy in HIV Infection. Birmingham (November 1996). Abstract SS2.1.
   Google Scholar
• GULICK RM, MELLORS J, HAVLIR D et al.: Potent and sustained antiretroviral activity of incinavir (IDV), zi-dovudine (ZDV) and lamivudine. XI International Confer-ence on AIDS. Vancouver (July 1996). Abstract Th.B.931.
   Google Scholar
• MOLLA A, KORNEYEVA M, GAO Q et al.: Ordered accu-mulations of mutations in HIV protease confers resis-tance to ritonavir. Nature Medicine (1996) 2:760–766.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, SCHLIEF WA, BLAHY OM et al.: In vivoemergence of 11IV-1 variants resistant to multiple pro-tease inhibitors. Nature (1995) 374:569–571.
   PubMed Web of Science ®Google Scholar
• JACOBSEN H, HANGGI M, OTT M et aL: In vivo resistanceto a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J. Infect. Dis. (1996) 173:1379–1387.
   PubMed Web of Science ®Google Scholar
• SHAPIRO JM, WINTERS MA, STEWART F et aL: The effectof high dose saquinavir on viral load and CD4 T-cell counts in HIV infected patients. Ann. Intern. Merl. (1996) 124:1039–1050.
   PubMed Web of Science ®Google Scholar
• MASCHERA B, TISDALE M, DARBY G et al: In vitrogrowth characteristics of 11IV-1 variants with reduced sensitiv-ity to saquinavir explain the appearance ofL9OM escape mutant in vivo. 5th International Workshop on HIV Drug Resistance. Whistler (3–6 July 1996). Abstract 85.
   Google Scholar
• CRAIG C, RACE E, SHELDON J et aL: Saquinavir (SQV) does not select for universal co-resistance with other prote-inase inhibitors (PO in patients. AIDS (1996) 10\(Suppl. 2):S22, Abstract P13.
   Google Scholar
• LECH WJ, WANG G, YANG YL et aL: In vivo sequence diversity of thr protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Vim]: (1996) 70:2038–2043.
   Google Scholar
• PATICK AK, DURAN M, CAO Y et aL: Genotypic andphenotypic characterisation of 11IV-1 variants isolated from in vitro sele ction studies and from patients treated with the protease inhibitor, nelfinavir. 5th International Workshop on HIV Drug Resistance. Whistler (3–6 July 1996). Abstract 29.
   Google Scholar
• TISDALE M, MYERS R, NAJERA I et aL: Analysis of resis-tance interactions with 141W94 (VX-478) and other protease inhibitors. 5th International Workshop on HIV Drug Resistance. Whistler (3–6 July 1996). Abstract 27.
   Google Scholar
• GAO WY, AGBARIA R, DRISCOLL JS, MITSUYA H: Diver-gent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2'3'-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. (1994) 269:12633–12638.
   PubMed Web of Science ®Google Scholar
• PORTEGIES P. 11IV-1, the brain and combination ther-apy. Lancet (1995) 346:1244–1245.
   PubMed Web of Science ®Google Scholar